
Novo Nordisk's oral semaglutide launch shows slower dose growth amid strong injectable competition.
Novo Nordisk's investor relations highlighted that the launch of its oral semaglutide is progressing with dose escalation patterns differing from its injectable forms. Despite improved data capture at 65%, 90% of prescriptions are still paid out-of-p...


